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OBJECTIVE — The purpose of this study was to determine longitudinal predictors of cog-
nitive decline in older individuals with diabetes who did not have dementia.
RESEARCH DESIGN AND METHODS — Cognitive assessments were performed in
205 subjects with diabetes (mean age 75.3 years) and repeated a median 1.6 years later. The
sample was drawn from an existing cohort study, and data on diabetes, cardiovascular risk
factors, and complications were collected 7.6  1.1 years before and at the time of the initial
cognitive assessment. Cognitive status was deﬁned using the Clinical Dementia Rating (CDR)
scale, and cognitive decline was deﬁned by change in CDR.
RESULTS — The sample included 164 subjects with normal cognition (CDR 0) and 41 with
cognitive impairment without dementia (CDR 0.5). At follow-up, 33 (16.1%) had experienced
cognitive decline (4 new cases of dementia and 29 cognitive impairment without dementia).
Onlyeducationalattainmentpredictedcognitivedeclinefromthedatacollected7.6yearsbefore
cognitive assessment. Univariate predictors of cognitive decline at the time of the ﬁrst cognitive
assessment included age, education, urinary albumin-to-creatinine ratio (ACR), and treatment
with either ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). With multiple
logistic regression controlling for age and education, cognitive decline was predicted by natural
logarithm ACR (odds ratio 1.37 [95% CI 1.05–1.78], P  0.021), whereas treatment with either
ACEIs or ARBs was protective (0.28 [0.12–0.65], P  0.003).
CONCLUSIONS — In this sample of older patients with diabetes, microalbuminuria was a
risk factor for cognitive decline, whereas drugs that inhibit the renin-angiotensin system were
protective. These observations require conﬁrmation because of their considerable potential
clinical implications.
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I
t has been established from longitudi-
nalstudiesthatinolderindividuals,di-
abetes is a risk factor for dementia and
for cognitive decline (1,2). Recent studies
also indicated that older patients with di-
abetes have an increased risk of having
milder degrees of cognitive impairment
(3,4). These patients may have a higher-
than-normal likelihood of progressing to
dementia. Most studies have deﬁned cog-
nitive decline by a change in neurocogni-
tive test scores, and the clinical relevance
of this information can be unclear. In ad-
dition, there have been few longitudinal
studiesofthecausesofmildcognitiveim-
pairment in diabetes.
There are many potential mecha-
nisms linking diabetes with cognitive de-
cline. Diabetes is a risk factor for
cerebrovascular disease that can cause
cognitive impairment due to ischemic
brain damage and may directly or indi-
rectly promote Alzheimer’s disease (5,6).
In addition, other processes related to di-
abetes, such as advanced glycation end
productaccumulationorchangesincere-
bral insulin signaling, may promote Alz-
heimer’s disease (7). Identiﬁed risk
factorsfordementiaandcognitivedecline
in diabetes have included hyperglycemia
(3,5), insulin therapy (8), duration of di-
abetes (9,10), and peripheral arterial dis-
ease (10). Most identiﬁed and possible
risk factors are interrelated, and few stud-
ies have comprehensively examined all po-
tential explanatory or confounding
variables. Microalbuminuria is an indepen-
dent cardiovascular risk factor of particu-
lar relevance in diabetes, and there have
beenrecentreportsofinverseassociations
between microalbuminuria and perfor-
mance on cognitive tests (11,12).
The aim of the present study was to
explore cardiovascular risk factors, in-
cluding microalbuminuria, for clinically
relevant cognitive decline in a sample
of diabetic patients with dementia who
had undergone a comprehensive assess-
ment encompassing a range of relevant
variables.
RESEARCH DESIGN AND
METHODS— The sample was drawn
from surviving participants of the
Fremantle Diabetes Study (FDS), who
were aged 70 years between 1 February
2001 and 31 December 2002 and who
participated in a study of cognition and
dementia (10). The FDS originally re-
cruited 1,426 diabetic patients (63%) of
2,258 identiﬁed from a postal code–
deﬁned region between 1993 and 1996,
ofwhom91%hadtype2diabetes.Details
of the recruitment procedures and the
characteristics of the original sample have
been described previously (13). For the
cognition study (10), 302 of 587 eligible
FDS survivors (51.4%) underwent cogni-
tiveassessmentsand275didnothavede-
mentia. Of these, 205 underwent a
secondcognitiveassessment18months
later. These participants comprise the
present study sample. Reasons for non-
participationinthesecondassessmentin-
cluded death (10.6%) and refusal
(14.6%). The Human Rights Committee,
Fremantle Hospital, approved the study,
and all participants gave written, in-
formed consent.
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All subjects provided sociodemographic
and clinical data at entry into the FDS.
Thesewereupdatedatthetimeofrecruit-
ment to the present study as part of a de-
tailed review comprising cognitive
assessment, clinical history (including
medications taken), and physical exami-
nation. Fasting blood and urine samples
were taken for automated biochemical
tests including serum glucose, A1C, li-
poproteins, creatinine, urinary albumin-
to-creatinine ratio (ACR) (14), and
apolipoprotein E genotype (APOE).
Complications were identiﬁed using
standard deﬁnitions. Peripheral sensory
neuropathy was deﬁned as a score of 2
of 8 on the clinical portion of the Michi-
gan Neuropathy Screening Instrument.
Nephropathy was deﬁned as a urinary
ACR 3.0 mg/mmol in an early-morning
urine sample (14). Creatinine clearance
was assessed using the Cockcroft-Gault
equation. Cerebrovascular disease was
deﬁned by self-reported stroke and tran-
sient ischemic attack supplemented by
scrutiny of hospital records. Coronary
heart disease was deﬁned if there was a
self-reported history of (or hospitaliza-
tion for) myocardial infarction, angina,
coronary artery bypass grafting, or
angioplasty and/or deﬁnite myocardial
infarction on a Minnesota coded electro-
cardiogram (14). The ankle-to-brachial
index (ABI) was obtained from brachial
and ankle systolic blood pressures using
Dopplerdetection.Peripheralarterialdis-
easewasconsideredpresentwhentheABI
was0.90(worseside)ortherehadbeen
a diabetes-related lower-extremity ampu-
tation (15). Depression was assessed us-
ing the Even Briefer Assessment Scale for
Depression (16). A history of hypoglyce-
mia was assessed by self-report at initial
recruitment (frequency), and questions
on severe hypoglycemia (hospitalization
or unconsciousness, frequency, and tim-
ing)wereincludedatthetimeofcognitive
assessment.
Cognitive assessment
Atwo-stepprocedurewasusedforassess-
ment of cognitive function, with initial
screening followed by detailed assess-
ment as described previously (10). The
method is sensitive and detects early cog-
nitiveimpairment(10).Apositivescreen-
ing test was deﬁned by a Mini-Mental
State Examination (MMSE) score 28/30
or a score 3.31 on the Informant Ques-
tionnaire for Cognitive Decline in the El-
derly (IQCODE) (17) or a positive
response to a question on subjective
memoryloss.Screen-positiveparticipants
and an additional random sample of 34
screen-negative participants underwent
1) neurocognitive testing (global cogni-
tion, premorbid intelligence, memory,
language, visuospatial, and executive
functions; data not presented) and 2)a
clinical assessment to exclude dementia
by experienced clinicians (D.G.B.,
R.M.C., and O.P.A.) that included an in-
formant whenever possible and scrutiny
ofhospitalrecordsforsupplementaldata.
Ratings of functional capacity were con-
ducted by a trained researcher using the
Clinical Dementia Rating (CDR) scale,
wherein a global CDR is derived by an
algorithm using an online computer
scoring program to generate ﬁnal scores
from ratings of six component domains
(memory, orientation, judgment/
problem solving, community affairs,
home/hobbies, and personal care) ob-
tained from patients and informants (18).
A CDR of 0.5 denoted an intermediate
state between normal cognition and de-
mentia (sometimes called very mild,
early, or questionable dementia) and was
designated cognitive impairment without
dementiainthepresentstudybecausethe
subjectshadundergoneclinicalexclusion
of dementia using the Diagnostic and Sta-
tistical Manual of Mental Disorders (4th
ed.) criteria. The screen-negative sub-
jectswhounderwentthefullcognitiveas-
sessment procedure were all assessed
as being cognitively normal (10); hence,
all screen-negative participants were
classiﬁed as having normal cognition. All
cognitive diagnoses were ﬁnalized at con-
sensus meetings of the investigators using
all available information. Cognitive de-
cline was deﬁned as a change in classiﬁ-
cation either from normal cognition to
dementia/cognitive impairment without
dementia or from cognitive impairment
without dementia to dementia.
Statistics
ThecomputerpackageSPSSforWindows
(version 11.5, SPSS, Chicago, IL) was
used. Data are presented as proportions,
means  SD, geometric means (SD
range),or(inthecaseofvariablesthatdid
not conform to a normal or log-normal
distribution) medians and interquartile
range (IQR). Two-sample comparisons of
proportions were performed by Fisher’s
exact test; for normally distributed vari-
ables, by Student’s t test; and for non-
normally distributed variables, by the
Mann-Whitney U test. Multiple logistic
regression analysis using forward condi-
tional modeling (P  0.05 for entry and
P  0.10 for removal) was performed to
determineindependentpredictorsofcog-
nitivedecline.Allclinicallyplausiblevari-
ables with P  0.20 in the respective
bivariate analyses were considered for the
models.
RESULTS
Sample characteristics and
prevalence of cognitive decline
At the time of the ﬁrst cognitive assess-
ment, the 205 study participants were
aged 75.0  4.1 years, 48.3% were male,
all had type 2 diabetes, and one lived in
residential care. They included 164 par-
ticipants with normal cognition (77.4%
with MMSE scores 28 and 16.6% with
IQCODE scores 3.31) and 41 with cog-
nitive impairment without dementia
(51.2% with MMSE scores 28 and
68.3% with IQCODE scores 3.31). The
eligible FDS subjects who did not partic-
ipate were older (77.5  4.9 years, P 
0.001) and had more cognitive impair-
ment without dementia (32.9% vs.
20.0%, P  0.034). After a median 1.6
(IQR 1.4–1.8) years follow-up, 33
(16.1%) had experienced cognitive de-
cline, of whom 4 were new cases of de-
mentia (2.0%) and 29 were new cases of
cognitive impairment without dementia
(14.1%). Of the four participants with
newcasesofdementia,onedeclinedfrom
normal to dementia whereas the other
three had cognitive impairment without
dementia at baseline.
Predictors of cognitive decline
Table 1 summarizes demographic and
clinical variables that were assessed at the
time of the ﬁrst cognitive assessment clas-
siﬁed by the presence or absence of sub-
sequent cognitive decline. Compared
with those with stable cognition, partici-
pants with cognitive decline were older,
had achieved lower levels of schooling,
had lower MMSE scores, were less likely
to be receiving insulin therapy, had
higher ACR and more clinical albumin-
uria, and were less likely to be taking an-
tihypertensive medications. In particular,
they were less likely to be taking either
ACEinhibitors(ACEIs)orangiotensinre-
ceptorblockers(ARBs),withnobetween-
group differences in other classes of
antihypertensive medications. There
werenodifferencesinserumcreatinineor
calculated rates of creatinine clearance
(data not shown).
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to investigate predictors of cognitive de-
cline, and all clinically plausible variables
with P  0.2 in the univariate analyses
were included in the model, i.e., age, ed-
ucation, presence of cognitive impair-
ment without dementia, insulin
treatment, taking antihypertensive medi-
cations, natural logarithm (ln) ACR, and
neuropathy (MMSE was not included,
given its strong association with cognitive
impairment without dementia). In this
model, the independent predictors of
cognitive decline were lnACR (odds ratio
1.32[95%CI1.02–1.69],P0.033)and
education beyond the primary school
level (0.28 [0.12–0.65], P  0.003),
which was protective, and insulin treat-
ment(0.31[0.10–0.99],P0.049),also
protective. In a second model with the
binary variable being treatment/no treat-
ment with ACEIs or ARBs substituted for
antihypertensive treatment, signiﬁcant
predictors of cognitive decline were
lnACR (1.37 [1.05–1.78], P  0.021),
with both higher education (0.32 [0.14–
0.76], P  0.009) and treatment with
ACEIs/ARBs (0.28 [0.12–0.65], P 
0.003) being protective.
Subjects with normal cognition
In the subgroup of 164 participants with
normal cognition, 29 experienced cogni-
tive decline (28 to cognitive impairment
without dementia [17.1%] and 1 case of
dementia) after a median 1.6 [IQR 1.4–
1.8] years (Table 2). The variables signif-
icantly associated with cognitive decline
in univariate analyses were age, educa-
tion, MMSE scores, treatment with any
antihypertensive drugs, treatment with
ACEIs or ARBs, and lnACR. In multiple
logisticregressionanalyses,incorporating
clinically plausible variables with univar-
iate P values  0.2 into the models, inde-
pendent predictors of cognitive decline
were lnACR (1.53 [1.14–2.06], P 
0.005), education beyond primary level
(0.29 [0.11–0.73], P  0.009), and tak-
ing antihypertensive medications (0.33
[0.11–0.97], P  0.043). When treat-
ment with ACEI or ARB drugs was substi-
tuted for antihypertensive medications,
cognitive decline was predicted indepen-
dently by lnACR (1.50 [1.10–2.04], P 
0.010), education beyond the primary
level (0.22 [0.09–0.58], P  0.002), and
ACEI/ARBs (0.24 [0.09–0.62], P 
0.003), which were protective.
Predictors from FDS recruitment
(1993–1996)
We performed the same analyses using
variables obtained at entry into the FDS
7.6  1.1 years before the ﬁrst cognitive
assessment.Comparedwithsubjectswho
exhibited a subsequent cognitive decline,
those without cognitive decline were
younger(67.14.0vs.68.94.7years,
P  0.024) and more likely to be edu-
cated beyond the primary level (81.9 vs.
51.5%, P  0.001). Prevalence of micro-
or macroalbuminuria (30.0 vs. 39.4%)
and use of ACEIs (17.4 vs. 15.2%) were
similar. Only educational attainment was
independently associated with cognitive
decline in the regression model (median
0.24 [IQR 0.11–0.52], P  0.001). Vir-
tually identical results were obtained
when only subjects with normal cogni-
tion were analyzed separately (data not
shown).
CONCLUSIONS — In the present
study, almost 16% of a community-based
sample of older patients with type 2 dia-
betes experienced a clinically relevant de-
cline in cognitive function after 1.6 years
offollow-up.Aftercontrollingforage,ed-
ucation,andcognitivefunction,cognitive
declinewaspredictedbyurinaryalbumin
excretion rates, whereas the use of either
ACEIs or ARBs appeared to be protective.
Theseﬁndingswerereplicatedinthesub-
group of subjects who were cognitively
normal. No clinical variables assessed an
Table 1—Demographic and clinical variables at the time of ﬁrst cognitive assessment in
subjectswhodidordidnotexperienceasubsequentdeclineincognitivefunctionafteramedian
1.6 years
No cognitive
decline
Cognitive
decline P value*
n 172 33
Age at assessment (years) 74.7  4.0 76.3  4.4 0.037
Sex (% male) 50.0 39.4 0.34
Education (%  primary schooling) 81.9 51.5 0.001
Cognitive impairment, no dementia (%) 22.0 9.4 0.10
Subjective memory complaints (%) 37.1 37.5 1.00
MMSE score 28 27–29 26 25–28 0.001
IQCODE 3.31 (%) 24.6 24.2 1.00
Duration of diabetes (years) 11.1 8.3–16.1 9.6 7.9–15.1 0.31
Diabetic treatment, diet only (%) 15.7 24.2 0.31
Oral hypoglycemic agents (%) 55.2 63.6 0.45
Insulin ( oral hypoglycemic therapy) (%) 29.1 12.1 0.052
Fasting glucose (mmol/l) 7.9 6.6–9.4 8.2 5.6–9.8 0.73
A1C (%) 7.0 6.5–7.9 7.5 6.3–8.2 0.64
BMI (kg/m
2) 28.9  4.6 28.4  4.2 0.61
Overweight/obese waist-to-hip ratio (%) 76.0 72.7 0.66
History of severe hypoglycemia (%) 6.6 9.1 0.71
Systolic blood pressure (mmHg) 151  24 151  20 0.88
Diastolic blood pressure (mmHg) 76  17 78  19 0.54
Antihypertensive medication (%) 84.0 68.8 0.049
Treatment with ACEIs or ARBs (%) 64.0 33.3 0.002
Cholesterol (mmol/l) 4.7  0.8 4.8  1.2 0.77
HDL cholesterol (mmol/l) 1.3  0.4 1.2  0.4 0.48
Serum triglycerides (mmol/l) 1.5 (0.9–2.5) 1.4 (0.8–2.3) 0.37
Lipid-lowering medication (%) 60.0 50.0 0.33
Albumin-to-creatinine ratio (mg/mmol) 2.7 (0.7–10.9) 6.0 (1.0–34.3) 0.020
Nephropathy (%) 42.9 62.5 0.052
Serum creatinine (mol/l) 91 (65–129) 86 (63–119) 0.40
Peripheral neuropathy (%) 27.1 43.8 0.09
Peripheral arterial disease (%) 35.7 43.8 0.43
Coronary heart disease (%) 32.4 30.3 1.00
Cerebrovascular disease (%) 20.1 24.2 0.64
Depression (%) 13.5 15.2 0.78
APOE e4 carriers (%) 21.8 12.1 0.25
DataaremeanSD,%,medianinterquartilerange,orgeometricrange(SDrange).*Appropriatebivariate
statistic.
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nitive decline, possibly because the prev-
alenceofmicroalbuminuriaandtheuseof
ACEIs or ARBs were relatively low.
Although microalbuminuria is com-
mon in the community, affecting 29% of
individualswithdiabetes,16%ofpatients
with hypertension, and 5% of healthy in-
dividuals (19), there are few data on its
association with cognitive function. Two
recent cross-sectional studies have re-
ported ﬁndings consistent with the
present study. In a study of subjects with
type 2 diabetes, those with microalbu-
minuriahadlowerMMSEscores(11).Ina
population-based study, microalbumin-
uria inversely correlated with test scores
of visuospatial function and motor speed
insubjectswithperipheralarterialdisease
(12).Incontrast,astudyconductedinthe
Rancho Bernardo cohort showed no asso-
ciation between microalbuminuria and
cognitive decline (20).
Microalbuminuria is a risk factor for
cardiovascular disease independently of
renal function and conventional cardio-
vascular risk factors, and there is an in-
creased risk even with low-grade
albuminuria (19). In the present study,
urinary albumin excretion assessed as a
continuousvariablewasmorestronglyas-
sociated with cognitive decline than the
presence of categorical microalbuminuria
or albuminuria. There was no association
with renal dysfunction as assessed from
creatinine clearance. Microalbuminuria
has been associated with stroke and cere-
bral small vessel ischemia (21); hence, a
vascularmechanismmayexplainitseffect
on cognitive decline. Additional possibil-
ities include endothelial dysfunction and
chroniclow-gradeinﬂammation.Bothare
associated with microalbuminuria in type
2 diabetes (22) and may have a role in the
pathogenesis of Alzheimer’s disease.
The protective effect of antihyperten-
sive therapy was explained by the use of
either ACEIs or ARBs. These two drug
classes have nearly identical effects on the
renin-angiotensin system and are known
to reduce urinary albumin excretion and
protect the kidney against diabetic ne-
phropathy. Some of these beneﬁcial ef-
fects may occur independently of blood
pressure lowering, possibly by reducing
inﬂammation in diabetic patients with
microalbuminuria (23). Blood pressure
loweringhasbeenshowntobeeffectivein
preventing stroke-related dementia, but
the data on Alzheimer’s disease are con-
ﬂicting (24). The use of ACEIs was asso-
ciated with reduced progression to
dementia in patients with mild cognitive
impairment (25) but not incident Alzhei-
mer’s disease in a population-based
study (26).
The strengths of the present study in-
clude its community-based sample, the
large number of older diabetic subjects,
the use of a clinically meaningful classiﬁ-
cation of cognitive decline, and the de-
tailed nature of the clinical assessment,
whichallowedustocontrolforimportant
modiﬁers, including education. The ma-
jor limitations of the study are the rela-
tively small sample size and the inherent
features of cohort studies with potential
biases at the recruitment phases and dif-
ferential dropout rates. Attrition between
FDS entry and recruitment to the present
study was substantial. The FDS survivors
who did not participate in the present
cognitive study were older and more
likely to have both cognitive impairment
and chronic complications than those
who were recruited. Because our sample
was almost entirely community dwelling
and relatively healthy and because the
rate of decline from normal to CDR stage
0.5 found in our patients was similar to
published annual conversion rates of
11.8–15.3% in aged populations (27),
the true rate of decline in diabetes may be
higher. Cognitive status was not assessed
atFDSentry,whichwouldhaveprovided
useful additional prospective data. The
generalizability of the ﬁndings beyond
those with diabetes is uncertain.
In summary, we found that clinical
cognitive decline was a common occur-
rence in a sample of older diabetic indi-
viduals and was predicted by increased
urinary albumin excretion, a potentially
modiﬁable risk factor. The independent
inverse association between ACEI or ARB
therapy and cognitive decline suggests
that these drug classes act through mech-
anisms distinct from those which act to
reduce urinary protein excretion. These
ﬁndings are of potential clinical impor-
tanceandfurtherconﬁrmatorystudiesare
needed in both diabetic and nondiabetic
populations.
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Table 2—Demographic and clinical variables in cognitively normal subjects who did or not
experience cognitive decline
No cognitive
decline
Cognitive
decline P value*
n 134 30
Age at assessment (years) 74.4  3.9 76.2  4.5 0.025
Sex (% male) 45.5 36.7 0.42
Education (%  primary schooling) 84.2 50.0 0.001
MMSE score 28 27–29 26 25–28 0.001
IQCODE 3.31 (%) 14.3 20.0 0.41
Duration of diabetes (years) 10.5 8.2–15.7 9.6 8.0–14.5 0.64
Oral hypoglycemic agents (%) 54.5 63.3 0.42
Insulin ( oral hypoglycemic therapy) (%) 27.6 13.3 0.16
A1C (%) 7.0 6.5–7.9 7.5 6.5–8.2 0.35
BMI (kg/m
2) 28.7  4.8 28.2  4.2 0.62
History of severe hypoglycemia (%) 4.6 6.7 0.65
Systolic blood pressure (mmHg) 150  24 152  20 0.75
Diastolic blood pressure (mmHg) 75  17 78  20 0.50
Antihypertensive medication (%) 84.8 69.0 0.060
Treatment with ACEIs or ARBs (%) 64.9 36.7 0.007
Albumin-to-creatinine ratio (mg/mmol) 2.8 (0.7–11.2) 7.0 (1.3–37.9) 0.003
Nephropathy (%) 45.1 65.5 0.063
Peripheral neuropathy (%) 26.5 41.4 0.12
Peripheral arterial disease (%) 34.6 44.8 0.39
Cerebrovascular disease (%) 15.2 23.3 0.29
Depression (%) 11.3 16.7 0.54
APOE e4 carriers (%) 22.0 10.0 0.20
DataaremeanSD,%,medianinterquartilerange,orgeometricrange(SDrange).*Appropriatebivariate
statistic.
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